Atorvastatin use in specific populations: Difference between revisions

Revision as of 15:03, 30 January 2014

Atorvastatin
Lipitor^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials
ClinicalTrials.gov

Hepatic impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease.

Revision as of 22:33, 29 January 2014 (view source) Pratik Bahekar (talk \| contribs) No edit summary ← Older edit		Revision as of 15:03, 30 January 2014 (view source) Pratik Bahekar (talk \| contribs) No edit summary Newer edit →
Line 1:		Line 1:
	{{Atorvastatin}}		{{Atorvastatin}}

	Hepatic impairment: Plasma concentrations markedly increased in patients with chronic alcoholic liver disease.		[[Hepatic impairment]]: Plasma concentrations markedly increased in patients with chronic [[alcoholic liver disease]].